Evidence Snapshot

Receptor-interacting serine/threonine-protein kinase 2

CHEMBL5014 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:05:08Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 5:05 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL5014

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Receptor-interacting serine/threonine-protein kinase 2 as ChEMBL target CHEMBL5014, mapped to UniProt O43353. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Receptor-interacting serine/threonine-protein kinase 2

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL5014

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

O43353

Receptor-interacting serine/threonine-protein kinase 2

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Receptor-interacting serine/threonine-protein kinase 2 matters

As of 2026-09-13

Receptor-interacting serine/threonine-protein kinase 2 is reviewed as Receptor-interacting serine/threonine-protein kinase 2 (UniProt O43353); the current evidence base includes 31 approved drugs, 1598 compounds, and 417 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Receptor-interacting serine/threonine-protein kinase 2

Receptor-interacting serine/threonine-protein kinase 2 Sequence length is 540 aa.

Review this target as Receptor-interacting serine/threonine-protein kinase 2, mapped to UniProt O43353. Sequence length is 540 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt O43353 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 31 approved drugs, 1598 compounds, and 417 assays for this target. The dominant activity type is IC50. CHEMBL4531690 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4531690 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

31 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Receptor-interacting serine/threonine-protein kinase 2 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O43353, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1598

Total Compounds

417

Total Assays

Approved Drugs

IC50: 1048.0, KI: 1.0, KD: 427.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL4531690	11.0	IC50	—
No preferred name CHEMBL4857880	10.0	IC50	—
No preferred name CHEMBL4866182	9.8	IC50	—
No preferred name CHEMBL5177284	9.6	Kd	—
No preferred name CHEMBL5177284	9.2	IC50	—

Approved Drugs

Structure	Compound	First Approval
	ENCORAFENIB CHEMBL3301612	2018
	DACOMITINIB ANHYDROUS CHEMBL2110732	2018
	GILTERITINIB CHEMBL3301622	2018
	TIVOZANIB CHEMBL1289494	2017
	LENVATINIB CHEMBL1289601	2015
	IBRUTINIB CHEMBL1873475	2013
	DABRAFENIB CHEMBL2028663	2013
	REGORAFENIB CHEMBL1946170	2012
	PONATINIB CHEMBL1171837	2012
	CABOZANTINIB CHEMBL2105717	2012
	VEMURAFENIB CHEMBL1229517	2011
	VANDETANIB CHEMBL24828	2011
	CRIZOTINIB CHEMBL601719	2011
	PAZOPANIB CHEMBL477772	2009
	DASATINIB CHEMBL5416410	2006
	SORAFENIB CHEMBL1336	2005
	ERLOTINIB CHEMBL553	2004
	GEFITINIB CHEMBL939	2003

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:05:08Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 5:05 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL5014